O	O	0	7	Aspirin	Aspirin	B-NP	NN	O	2	SUB	O
O	O	8	16	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	O
T21	B-Entity	17	24	nuclear	nuclear	B-NP	JJ	B-protein	7	NMOD	B-protein
T21	I-Entity	25	31	factor	factor	I-NP	NN	I-protein	7	NMOD	I-protein
T21	I-Entity	31	32	-	-	B-NP	HYPH	I-protein	7	NMOD	I-protein
T21	I-Entity	32	37	kappa	kappa	I-NP	NN	I-protein	7	NMOD	I-protein
T21	I-Entity	38	39	B	B	I-NP	NN	I-protein	8	NMOD	I-protein
O	O	40	52	mobilization	mobilization	I-NP	NN	O	11	NMOD	O
O	O	53	56	and	and	I-NP	CC	O	11	NMOD	O
O	O	57	65	monocyte	monocyte	I-NP	NN	O	11	NMOD	O
O	O	66	74	adhesion	adhesion	I-NP	NN	O	2	OBJ	O
O	O	75	77	in	in	B-PP	IN	O	11	NMOD	O
O	O	78	88	stimulated	stimulate	B-NP	VBN	B-cell_line	16	NMOD	B-cell_line
O	O	89	94	human	human	I-NP	JJ	I-cell_line	16	NMOD	I-cell_line
O	O	95	106	endothelial	endothelial	I-NP	JJ	I-cell_line	16	NMOD	I-cell_line
O	O	107	112	cells	cell	I-NP	NNS	I-cell_line	12	PMOD	I-cell_line
O	O	112	113	.	.	O	.	O	2	P	O

O	O	115	125	BACKGROUND	BACKGROUND	B-NP	NN	O	0	ROOT	O
O	O	125	126	:	:	O	:	O	1	P	O
O	O	127	130	The	The	B-NP	DT	O	4	NMOD	O
O	O	131	140	induction	induction	I-NP	NN	O	30	SUB	O
O	O	141	143	of	of	B-PP	IN	O	4	NMOD	O
T1	B-Protein	144	152	vascular	vascular	B-NP	JJ	B-protein	9	NMOD	B-protein
T1	I-Protein	153	157	cell	cell	I-NP	NN	I-protein	9	NMOD	I-protein
T1	I-Protein	158	166	adhesion	adhesion	I-NP	NN	I-protein	9	NMOD	I-protein
T1	I-Protein	167	175	molecule	molecule	I-NP	NN	I-protein	11	NMOD	I-protein
T1	I-Protein	175	176	-	-	B-NP	HYPH	O	11	P	O
T1	I-Protein	176	177	1	1	I-NP	CD	O	20	NMOD	O
O	O	178	179	(	(	O	(	O	16	DEP	O
T2	B-Protein	179	183	VCAM	VCAM	B-NP	NN	B-protein	14	NMOD	B-protein
T2	I-Protein	183	184	-	-	B-NP	HYPH	I-protein	16	DEP	I-protein
T2	I-Protein	184	185	1	1	I-NP	CD	I-protein	14	NMOD	I-protein
O	O	185	186	)	)	O	)	O	11	NMOD	O
O	O	187	190	and	and	O	CC	O	20	NMOD	O
T3	B-Protein	191	192	E	E	B-NP	NN	B-protein	20	NMOD	B-protein
T3	I-Protein	192	193	-	-	O	HYPH	I-protein	20	NMOD	I-protein
T3	I-Protein	193	201	selectin	selectin	B-NP	NN	I-protein	5	PMOD	I-protein
O	O	202	204	by	by	B-PP	IN	O	4	NMOD	O
T4	B-Protein	205	210	tumor	tumor	B-NP	NN	B-protein	24	NMOD	B-protein
T4	I-Protein	211	219	necrosis	necrosis	I-NP	NN	I-protein	24	NMOD	I-protein
T4	I-Protein	220	226	factor	factor	I-NP	NN	I-protein	26	NMOD	I-protein
T4	I-Protein	226	227	-	-	O	HYPH	O	26	P	O
T4	I-Protein	227	232	alpha	alpha	B-NP	SYM	O	21	PMOD	O
O	O	233	234	(	(	O	(	O	29	DEP	O
T5	B-Protein	234	237	TNF	TNF	B-NP	NN	B-protein	29	DEP	B-protein
O	O	237	238	)	)	O	)	O	26	NMOD	O
O	O	239	241	is	be	B-VP	VBZ	O	1	NMOD	O
O	O	242	250	mediated	mediate	I-VP	VBN	O	30	VC	O
O	O	251	253	by	by	B-PP	IN	O	31	VMOD	O
O	O	254	266	mobilization	mobilization	B-NP	NN	O	32	PMOD	O
O	O	267	269	of	of	B-PP	IN	O	33	NMOD	O
O	O	270	273	the	the	B-NP	DT	O	39	NMOD	O
O	O	274	287	transcription	transcription	I-NP	NN	B-protein	39	NMOD	B-protein
O	O	288	294	factor	factor	I-NP	NN	I-protein	39	NMOD	I-protein
T22	B-Entity	295	302	nuclear	nuclear	B-NP	JJ	I-protein	39	NMOD	I-protein
T22	I-Entity	303	309	factor	factor	I-NP	NN	I-protein	42	NMOD	I-protein
T22	I-Entity	309	310	-	-	B-NP	HYPH	O	42	NMOD	O
T22	I-Entity	310	315	kappa	kappa	I-NP	NN	O	42	NMOD	O
T22	I-Entity	316	317	B	B	I-NP	NN	O	34	PMOD	O
O	O	318	319	(	(	O	(	O	48	DEP	O
T23	B-Entity	319	321	NF	NF	B-NP	NN	B-protein	47	NMOD	B-protein
T23	I-Entity	321	322	-	-	B-NP	HYPH	I-protein	47	NMOD	I-protein
T23	I-Entity	322	327	kappa	kappa	I-NP	NN	I-protein	47	NMOD	I-protein
T23	I-Entity	328	329	B	B	I-NP	NN	I-protein	48	DEP	I-protein
O	O	329	330	)	)	O	)	O	42	NMOD	O
O	O	330	331	.	.	O	.	O	30	P	O

O	O	332	337	Since	Since	B-SBAR	IN	O	25	VMOD	O
O	O	338	349	salicylates	salicylate	B-NP	NNS	O	3	SUB	O
O	O	350	354	have	have	B-VP	VBP	O	1	SBAR	O
O	O	355	359	been	be	I-VP	VBN	O	3	VC	O
O	O	360	368	reported	report	I-VP	VBN	O	4	VC	O
O	O	369	371	to	to	I-VP	TO	O	7	VMOD	O
O	O	372	379	inhibit	inhibit	I-VP	VB	O	5	VMOD	O
T24	B-Entity	380	382	NF	NF	B-NP	NN	B-protein	11	NMOD	B-protein
T24	I-Entity	382	383	-	-	B-NP	HYPH	I-protein	11	NMOD	I-protein
T24	I-Entity	383	388	kappa	kappa	I-NP	NN	I-protein	11	NMOD	I-protein
T24	I-Entity	389	390	B	B	I-NP	NN	I-protein	12	NMOD	I-protein
O	O	391	401	activation	activation	I-NP	NN	O	7	OBJ	O
O	O	402	404	by	by	B-PP	IN	O	7	VMOD	O
O	O	405	415	preventing	prevent	B-VP	VBG	O	13	PMOD	O
O	O	416	419	the	the	B-NP	DT	O	16	NMOD	O
O	O	420	431	degradation	degradation	I-NP	NN	O	14	OBJ	O
O	O	432	434	of	of	B-PP	IN	O	16	NMOD	O
O	O	435	438	its	its	B-NP	PRP$	O	22	NMOD	O
O	O	439	448	inhibitor	inhibitor	I-NP	NN	O	22	NMOD	O
O	O	449	450	I	I	I-NP	NN	B-protein	22	NMOD	B-protein
O	O	451	456	kappa	kappa	I-NP	NN	I-protein	22	NMOD	I-protein
O	O	457	458	B	B	I-NP	NN	I-protein	17	PMOD	I-protein
O	O	458	459	,	,	O	,	O	25	P	O
O	O	460	462	we	we	B-NP	PRP	O	25	SUB	O
O	O	463	470	studied	study	B-VP	VBD	O	0	ROOT	O
O	O	471	472	a	a	B-NP	DT	O	28	NMOD	O
O	O	473	482	potential	potential	I-NP	JJ	O	28	NMOD	O
O	O	483	493	inhibition	inhibition	I-NP	NN	O	25	OBJ	O
O	O	494	496	of	of	B-PP	IN	O	28	NMOD	O
O	O	497	501	this	this	B-NP	DT	O	31	NMOD	O
O	O	502	509	pathway	pathway	I-NP	NN	O	29	PMOD	O
O	O	510	512	by	by	B-PP	IN	O	28	NMOD	O
O	O	513	529	acetylsalicylate	acetylsalicylate	B-NP	NN	O	32	PMOD	O
O	O	530	531	(	(	O	(	O	36	DEP	O
O	O	531	538	aspirin	aspirin	B-NP	NN	O	36	DEP	O
O	O	538	539	)	)	O	)	O	33	NMOD	O
O	O	540	542	in	in	B-PP	IN	O	28	NMOD	O
O	O	543	548	human	human	B-NP	JJ	B-cell_type	42	NMOD	B-cell_type
O	O	549	558	umbilical	umbilical	I-NP	JJ	I-cell_type	42	NMOD	I-cell_type
O	O	559	563	vein	vein	I-NP	NN	I-cell_type	42	NMOD	I-cell_type
O	O	564	575	endothelial	endothelial	I-NP	JJ	I-cell_type	42	NMOD	I-cell_type
O	O	576	581	cells	cell	I-NP	NNS	I-cell_type	37	PMOD	I-cell_type
O	O	582	583	(	(	O	(	O	45	DEP	O
O	O	583	589	HUVECs	HUVEC	B-NP	NNS	B-cell_line	45	DEP	B-cell_line
O	O	589	590	)	)	O	)	O	42	NMOD	O
O	O	590	591	.	.	O	.	O	25	P	O

O	O	592	599	METHODS	METHODS	B-NP	NNS	O	3	NMOD	O
O	O	600	603	AND	AND	I-NP	CC	O	3	NMOD	O
O	O	604	611	RESULTS	RESULTS	I-NP	NNS	O	0	ROOT	O
O	O	611	612	:	:	O	:	O	3	P	O
O	O	613	616	Gel	Gel	B-NP	NN	B-protein	8	NMOD	B-protein
O	O	616	617	-	-	B-NP	HYPH	O	8	NMOD	O
O	O	617	622	shift	shift	I-NP	NN	O	8	NMOD	O
O	O	623	631	analyses	analysis	I-NP	NNS	O	9	SUB	O
O	O	632	644	demonstrated	demonstrate	B-VP	VBD	O	3	NMOD	O
O	O	645	649	dose	dose	B-NP	NN	O	13	NMOD	O
O	O	649	650	-	-	B-NP	HYPH	O	13	NMOD	O
O	O	650	659	dependent	dependent	I-NP	JJ	O	13	NMOD	O
O	O	660	670	inhibition	inhibition	I-NP	NN	O	9	OBJ	O
O	O	671	673	of	of	B-PP	IN	O	13	NMOD	O
T6	B-Protein	674	677	TNF	TNF	B-NP	NN	B-protein	22	NMOD	B-protein
O	O	677	678	-	-	O	HYPH	O	22	P	O
O	O	678	685	induced	induce	B-NP	VBN	O	22	NMOD	O
T25	B-Entity	686	688	NF	NF	I-NP	NN	B-protein	22	NMOD	B-protein
T25	I-Entity	688	689	-	-	B-NP	HYPH	I-protein	22	NMOD	I-protein
T25	I-Entity	689	694	kappa	kappa	I-NP	NN	I-protein	22	NMOD	I-protein
T25	I-Entity	695	696	B	B	I-NP	NN	I-protein	22	NMOD	I-protein
O	O	697	709	mobilization	mobilization	I-NP	NN	O	14	PMOD	O
O	O	710	712	by	by	B-PP	IN	O	13	NMOD	O
O	O	713	720	aspirin	aspirin	B-NP	NN	O	23	PMOD	O
O	O	721	723	at	at	B-PP	IN	O	9	VMOD	O
O	O	724	738	concentrations	concentration	B-NP	NNS	O	25	PMOD	O
O	O	739	746	ranging	range	B-VP	VBG	O	26	NMOD	O
O	O	747	751	from	from	B-PP	IN	O	27	VMOD	O
O	O	752	753	1	1	B-NP	CD	O	28	AMOD	O
O	O	754	756	to	to	I-NP	TO	O	28	AMOD	O
O	O	757	759	10	10	I-NP	CD	O	28	AMOD	O
O	O	760	764	mmol	mmol	I-NP	NN	O	34	NMOD	O
O	O	764	765	/	/	I-NP	SYM	O	34	NMOD	O
O	O	765	766	L	L	I-NP	NN	O	28	PMOD	O
O	O	766	767	.	.	O	.	O	3	P	O

O	O	768	777	Induction	Induction	B-NP	NN	O	14	SUB	O
O	O	778	780	of	of	B-PP	IN	O	1	NMOD	O
T7	B-Protein	781	785	VCAM	VCAM	B-NP	NN	B-protein	11	NMOD	B-protein
T7	I-Protein	785	786	-	-	B-NP	HYPH	I-protein	3	NMOD	I-protein
T7	I-Protein	786	787	1	1	I-NP	CD	I-protein	4	NMOD	I-protein
O	O	788	791	and	and	I-NP	CC	O	11	NMOD	O
T8	B-Protein	792	793	E	E	I-NP	NN	B-protein	11	NMOD	B-protein
T8	I-Protein	793	794	-	-	B-NP	HYPH	I-protein	11	NMOD	I-protein
T8	I-Protein	794	802	selectin	selectin	I-NP	NN	I-protein	11	NMOD	I-protein
O	O	803	810	surface	surface	I-NP	NN	O	11	NMOD	O
O	O	811	821	expression	expression	I-NP	NN	O	2	PMOD	O
O	O	822	824	by	by	B-PP	IN	O	1	NMOD	O
T9	B-Protein	825	828	TNF	TNF	B-NP	NN	B-protein	12	PMOD	B-protein
O	O	829	832	was	be	B-VP	VBD	O	0	ROOT	O
O	O	833	837	dose	dose	B-NP	NN	O	14	PRD	O
O	O	837	838	-	-	B-VP	HYPH	O	15	P	O
O	O	838	849	dependently	dependently	I-VP	RB	O	15	AMOD	O
O	O	850	857	reduced	reduce	I-VP	VBN	O	15	NMOD	O
O	O	858	860	by	by	B-PP	IN	O	18	VMOD	O
O	O	861	868	aspirin	aspirin	B-NP	NN	O	19	PMOD	O
O	O	869	873	over	over	B-PP	IN	O	14	VMOD	O
O	O	874	877	the	the	B-NP	DT	O	24	NMOD	O
O	O	878	882	same	same	I-NP	JJ	O	24	NMOD	O
O	O	883	888	range	range	I-NP	NN	O	21	PMOD	O
O	O	888	889	,	,	O	,	O	14	P	O
O	O	890	895	while	while	B-SBAR	IN	O	14	VMOD	O
O	O	896	905	induction	induction	B-NP	NN	O	39	SUB	O
O	O	906	908	of	of	B-PP	IN	O	27	NMOD	O
T10	B-Protein	909	922	intercellular	intercellular	B-NP	JJ	B-protein	31	NMOD	B-protein
T10	I-Protein	923	931	adhesion	adhesion	I-NP	NN	I-protein	31	NMOD	I-protein
T10	I-Protein	932	940	molecule	molecule	I-NP	NN	I-protein	28	PMOD	I-protein
T10	I-Protein	940	941	-	-	B-NP	HYPH	O	27	P	O
T10	I-Protein	941	942	1	1	I-NP	CD	O	27	NMOD	O
O	O	943	944	(	(	O	(	O	38	DEP	O
T11	B-Protein	944	948	ICAM	ICAM	B-NP	NN	B-protein	36	NMOD	B-protein
T11	I-Protein	948	949	-	-	B-NP	HYPH	I-protein	38	DEP	I-protein
T11	I-Protein	949	950	1	1	I-NP	CD	I-protein	36	NMOD	I-protein
O	O	950	951	)	)	O	)	O	27	NMOD	O
O	O	952	955	was	be	B-VP	VBD	O	26	SBAR	O
O	O	956	962	hardly	hardly	I-VP	RB	O	39	VMOD	O
O	O	963	971	affected	affect	I-VP	VBN	O	39	VC	O
O	O	971	972	.	.	O	.	O	14	P	O

O	O	973	980	Aspirin	Aspirin	B-NP	NN	O	2	SUB	O
O	O	981	989	appeared	appear	B-VP	VBD	O	0	ROOT	O
O	O	990	992	to	to	I-VP	TO	O	4	VMOD	O
O	O	993	1000	prevent	prevent	I-VP	VB	O	2	VMOD	O
T12	B-Protein	1001	1005	VCAM	VCAM	B-NP	NN	B-protein	8	NMOD	B-protein
T12	I-Protein	1005	1006	-	-	B-NP	HYPH	O	8	NMOD	O
T12	I-Protein	1006	1007	1	1	I-NP	CD	O	8	NMOD	O
O	O	1008	1021	transcription	transcription	I-NP	NN	O	4	OBJ	O
O	O	1021	1022	,	,	O	,	O	2	P	O
O	O	1023	1028	since	since	B-SBAR	IN	O	2	VMOD	O
O	O	1029	1031	it	it	B-NP	PRP	O	12	SUB	O
O	O	1032	1036	dose	dose	B-NP	NN	O	15	SUB	O
O	O	1036	1037	-	-	B-ADJP	HYPH	O	12	P	O
O	O	1037	1048	dependently	dependently	B-ADVP	RB	O	15	VMOD	O
O	O	1049	1058	inhibited	inhibit	B-VP	VBD	O	10	SBAR	O
O	O	1059	1068	induction	induction	B-NP	NN	O	15	OBJ	O
O	O	1069	1071	of	of	B-PP	IN	O	16	NMOD	O
T13	B-Protein	1072	1076	VCAM	VCAM	B-NP	NN	B-RNA	21	NMOD	B-RNA
T13	I-Protein	1076	1077	-	-	B-NP	HYPH	I-RNA	21	NMOD	I-RNA
T13	I-Protein	1077	1078	1	1	I-NP	CD	I-RNA	21	NMOD	I-RNA
O	O	1079	1083	mRNA	mRNA	I-NP	NN	I-RNA	17	PMOD	I-RNA
O	O	1084	1086	by	by	B-PP	IN	O	16	NMOD	O
T14	B-Protein	1087	1090	TNF	TNF	B-NP	NN	B-protein	22	PMOD	B-protein
O	O	1090	1091	.	.	O	.	O	2	P	O

O	O	1092	1094	As	As	B-PP	IN	O	15	VMOD	O
O	O	1095	1096	a	a	B-NP	DT	O	4	NMOD	O
O	O	1097	1107	functional	functional	I-NP	JJ	O	4	NMOD	O
O	O	1108	1119	consequence	consequence	I-NP	NN	O	1	PMOD	O
O	O	1119	1120	,	,	O	,	O	15	P	O
O	O	1121	1129	adhesion	adhesion	B-NP	NN	O	15	SUB	O
O	O	1130	1132	of	of	B-PP	IN	O	6	NMOD	O
O	O	1133	1137	U937	U937	B-NP	NN	B-cell_line	9	NMOD	B-cell_line
O	O	1138	1147	monocytes	monocyte	I-NP	NNS	I-cell_line	7	PMOD	I-cell_line
O	O	1148	1150	to	to	B-PP	TO	O	6	NMOD	O
T15	B-Protein	1151	1154	TNF	TNF	B-NP	NN	B-protein	14	NMOD	B-protein
O	O	1154	1155	-	-	B-NP	HYPH	O	14	NMOD	O
O	O	1155	1165	stimulated	stimulate	I-NP	VBN	O	14	NMOD	O
O	O	1166	1172	HUVECs	HUVEC	I-NP	NNS	B-cell_line	10	PMOD	B-cell_line
O	O	1173	1176	was	be	B-VP	VBD	O	0	ROOT	O
O	O	1177	1185	markedly	markedly	I-VP	RB	O	15	VMOD	O
O	O	1186	1193	reduced	reduce	I-VP	VBN	O	15	VC	O
O	O	1194	1196	by	by	B-PP	IN	O	17	VMOD	O
O	O	1197	1204	aspirin	aspirin	B-NP	NN	O	18	PMOD	O
O	O	1205	1208	due	due	B-ADJP	JJ	O	19	NMOD	O
O	O	1209	1211	to	to	B-PP	TO	O	20	AMOD	O
O	O	1212	1223	suppression	suppression	B-NP	NN	O	21	PMOD	O
O	O	1224	1226	of	of	B-PP	IN	O	22	NMOD	O
T16	B-Protein	1227	1231	VCAM	VCAM	B-NP	NN	B-protein	31	NMOD	B-protein
T16	I-Protein	1231	1232	-	-	B-NP	HYPH	I-protein	24	NMOD	I-protein
T16	I-Protein	1232	1233	1	1	I-NP	CD	I-protein	25	NMOD	I-protein
O	O	1234	1237	and	and	I-NP	CC	O	31	NMOD	O
T17	B-Protein	1238	1239	E	E	I-NP	NN	B-protein	31	NMOD	B-protein
T17	I-Protein	1239	1240	-	-	B-NP	HYPH	I-protein	31	NMOD	I-protein
T17	I-Protein	1240	1248	selectin	selectin	I-NP	NN	I-protein	31	NMOD	I-protein
O	O	1249	1261	upregulation	upregulation	I-NP	NN	O	23	PMOD	O
O	O	1261	1262	.	.	O	.	O	15	P	O

O	O	1263	1268	These	These	B-NP	DT	O	2	NMOD	O
O	O	1269	1276	effects	effect	I-NP	NNS	O	5	SUB	O
O	O	1277	1279	of	of	B-PP	IN	O	2	NMOD	O
O	O	1280	1287	aspirin	aspirin	B-NP	NN	O	3	PMOD	O
O	O	1288	1292	were	be	B-VP	VBD	O	0	ROOT	O
O	O	1293	1296	not	not	O	RB	O	5	VMOD	O
O	O	1297	1304	related	related	B-ADJP	JJ	O	5	PRD	O
O	O	1305	1307	to	to	B-PP	TO	O	7	AMOD	O
O	O	1308	1311	the	the	B-NP	DT	O	10	NMOD	O
O	O	1312	1322	inhibition	inhibition	I-NP	NN	O	8	PMOD	O
O	O	1323	1325	of	of	B-PP	IN	O	10	NMOD	O
T26	B-Entity	1326	1340	cyclooxygenase	cyclooxygenase	B-NP	NN	B-protein	13	NMOD	B-protein
O	O	1341	1349	activity	activity	I-NP	NN	O	11	PMOD	O
O	O	1349	1350	,	,	O	,	O	5	P	O
O	O	1351	1356	since	since	B-SBAR	IN	O	5	VMOD	O
O	O	1357	1369	indomethacin	indomethacin	B-NP	NN	O	17	SUB	O
O	O	1370	1373	was	be	B-VP	VBD	O	15	SBAR	O
O	O	1374	1385	ineffective	ineffective	B-ADJP	JJ	O	17	PRD	O
O	O	1385	1386	.	.	O	.	O	5	P	O

O	O	1387	1398	CONCLUSIONS	CONCLUSIONS	B-NP	NNS	O	0	ROOT	O
O	O	1398	1399	:	:	O	:	O	1	P	O
O	O	1400	1403	Our	Our	B-NP	PRP$	O	4	NMOD	O
O	O	1404	1408	data	datum	I-NP	NNS	O	5	SUB	O
O	O	1409	1416	suggest	suggest	B-VP	VBP	O	1	NMOD	O
O	O	1417	1421	that	that	B-SBAR	IN	O	5	VMOD	O
O	O	1422	1429	aspirin	aspirin	B-NP	NN	O	8	SUB	O
O	O	1430	1438	inhibits	inhibit	B-VP	VBZ	O	6	SBAR	O
T27	B-Entity	1439	1441	NF	NF	B-NP	NN	B-protein	13	NMOD	B-protein
T27	I-Entity	1441	1442	-	-	I-NP	HYPH	I-protein	13	NMOD	I-protein
T27	I-Entity	1442	1447	kappa	kappa	I-NP	NN	I-protein	13	NMOD	I-protein
T27	I-Entity	1448	1449	B	B	I-NP	NN	I-protein	13	NMOD	I-protein
O	O	1450	1462	mobilization	mobilization	I-NP	NN	O	28	NMOD	O
O	O	1462	1463	,	,	O	,	O	28	P	O
O	O	1464	1473	induction	induction	B-NP	NN	O	28	NMOD	O
O	O	1474	1476	of	of	B-PP	IN	O	15	NMOD	O
T18	B-Protein	1477	1481	VCAM	VCAM	B-NP	NN	B-protein	23	NMOD	B-protein
T18	I-Protein	1481	1482	-	-	B-NP	HYPH	I-protein	17	NMOD	I-protein
T18	I-Protein	1482	1483	1	1	I-NP	CD	I-protein	18	NMOD	I-protein
O	O	1484	1487	and	and	I-NP	CC	O	23	NMOD	O
T19	B-Protein	1488	1489	E	E	I-NP	NN	B-protein	23	NMOD	B-protein
T19	I-Protein	1489	1490	-	-	O	HYPH	I-protein	23	NMOD	I-protein
T19	I-Protein	1490	1498	selectin	selectin	B-NP	NN	I-protein	16	PMOD	I-protein
O	O	1498	1499	,	,	O	,	O	28	P	O
O	O	1500	1503	and	and	O	CC	O	28	NMOD	O
O	O	1504	1514	subsequent	subsequent	B-NP	JJ	O	28	NMOD	O
O	O	1515	1523	monocyte	monocyte	I-NP	NN	O	28	NMOD	O
O	O	1524	1532	adhesion	adhesion	I-NP	NN	O	8	OBJ	O
O	O	1533	1535	in	in	B-PP	IN	O	28	NMOD	O
O	O	1536	1547	endothelial	endothelial	B-NP	JJ	B-cell_type	31	NMOD	B-cell_type
O	O	1548	1553	cells	cell	I-NP	NNS	I-cell_type	29	PMOD	I-cell_type
O	O	1554	1564	stimulated	stimulate	B-VP	VBN	O	31	NMOD	O
O	O	1565	1567	by	by	B-PP	IN	O	32	VMOD	O
T20	B-Protein	1568	1571	TNF	TNF	B-NP	NN	B-protein	33	PMOD	B-protein
O	O	1571	1572	,	,	O	,	O	8	P	O
O	O	1573	1580	thereby	thereby	B-VP	RB	O	37	VMOD	O
O	O	1581	1590	providing	provide	I-VP	VBG	O	8	VMOD	O
O	O	1591	1593	an	an	B-NP	DT	O	40	NMOD	O
O	O	1594	1604	additional	additional	I-NP	JJ	O	40	NMOD	O
O	O	1605	1614	mechanism	mechanism	I-NP	NN	O	37	OBJ	O
O	O	1615	1618	for	for	B-PP	IN	O	40	NMOD	O
O	O	1619	1630	therapeutic	therapeutic	B-NP	JJ	O	43	NMOD	O
O	O	1631	1638	effects	effect	I-NP	NNS	O	41	PMOD	O
O	O	1639	1641	of	of	B-PP	IN	O	43	NMOD	O
O	O	1642	1649	aspirin	aspirin	B-NP	NN	O	44	PMOD	O
O	O	1649	1650	.	.	O	.	O	1	P	O
